NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial
NALIRIFOX improved mPDAC survival versus Gem + NabP irrespective of patient age, with no signals for reduced tolerability in the older (versus younger) patients. The results provide reassurance that triplet therapy with NALIRIFOX is an efficacious and tolerable regimen in older treatment-naive patients with mPDAC who were fit enough for inclusion in NAPOLI 3, supporting consideration of its use as 1L therapy in this population.
Authors
- Z.A. Wainberg
- R. Hubner
- EM O’Reilly
- S. Pant
- J. -Y. Li
- A. Patel
- V. Chung
- A. Cubillo Gracian
- R.Pazo Cid
- F. Maxwell
- A.S. Paulson
- H. Hatoum
- E. Van Cutsem
- A. Zervoudakis
- D. Melisi
- M.S. Womack
- T. Bekaii-Saab
- T. Macarulla
- L. Zhang
- H. Chen
Institutions
- Hebron University (PS)
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Texas Oncology (US)
- Universitair Ziekenhuis Leuven (BE)
- Clinical Physiology Associates (US)
- Ipsen (United Kingdom) (GB)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Centro Oncológico de Galicia (ES)
- Los Angeles Medical Center (US)
- Vall d'Hebron Institut de Recerca (ES)
- Hospital Universitario Miguel Servet (ES)
- Florida Cancer Specialists & Research Institute (US)
- Mayo Clinic in Arizona (US)
- The Christie NHS Foundation Trust (GB)
- Tennessee Oncology (US)
- Ipsen (United States) (US)
- University of Oklahoma Health Sciences Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106043
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 24.20